What is the association between SGLT2 inhibitors and the risk of lower limb amputation in patients with type 2 diabetes?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18164914
Cited by: 0

Abstract

There is a potential increased risk of lower limb amputation associated with canagliflozin, an SGLT2 inhibitor, though evidence is mixed regarding whether this risk extends to the entire class of these medications.

Fields of Study & Subjects

Diabetes Treatment and Management Pancreatic function and diabetes Bariatric Surgery and Outcomes

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
6 January 2026